Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay.
Many biopharmaceuticals (BPs) are known to be immunogenic in the clinic, which can result in modified pharmacokinetics, reduced efficacy, allergic reactions and anaphylaxis. During recent years, several technologies to predict immunogenicity have been introduced, but the predictive value is still co...
Main Authors: | Heidi S Schultz, Stine Louise Reedtz-Runge, B Thomas Bäckström, Kasper Lamberth, Christian R Pedersen, Anne M Kvarnhammar, ABIRISK consortium |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5451071?pdf=render |
Similar Items
-
Phenotypes of cells infectable by dengue virus in PBMC of healthy donors
by: Sia-SengTan, et al.
Published: (2017) -
PBMC fixation and processing for Chromium single-cell RNA sequencing
by: Jinguo Chen, et al.
Published: (2018-07-01) -
Resting of Cryopreserved PBMC Does Not Generally Benefit the Performance of Antigen-Specific T Cell ELISPOT Assays
by: Ramu A. Subbramanian, et al.
Published: (2012-07-01) -
Whole-exome sequencing of DNA from peripheral blood mononuclear cells (PBMC) and EBV-transformed lymphocytes from the same donor
by: Delgrosso Kathleen, et al.
Published: (2011-09-01) -
Predicting the allergenicity of legume proteins using a PBMC gene expression assay
by: Mark Smits, et al.
Published: (2021-04-01)